ArticleJournal of cancer research and clinical oncology2023

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).

Mutlu Hizal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.